SymbolNASC
NameNASCENT PHARMA HOLDINGS INC.
SectorUNDEFINED
RegionNorth America
Industry-
Address11801 United States NY 960 South Broadway Suite 118
Telephone+1 5165959544
Fax
Email
Websitehttps://nascentpharmaholdings.com
IncorporationUS
Incorporated On2005
Employees
Fiscal Year12/31
Public Since
ExchangesOTC
AuditorHaynie & Company, CPA;
Audit StatusUNAUDITED
Reporting StatusAlternative Reporting Standard
CIK0002042814
Description

Our patent portfolio held by Can B Corp. in its Nascent Pharma, LLC Division includes three issued patents with claims to popular cannabis and hemp-based products and manufacturing methods that dominate the cannabis, hemp and CBD industry. The Can B patents were tested in an earlier litigation, survived, and now benefit from several favorable court rulings. The targeted industry includes the major cannabis industry leaders and supports a substantial damage model. The monetization project discussed below justifies the significant investment necessary for success.

Additional info from OTC:
Our patent portfolio held by Can B Corp. in its Nascent Pharma, LLC Division includes three issued patents with claims to popular cannabis and hemp-based products and manufacturing methods that dominate the cannabis, hemp and CBD industry. The Can B patents were tested in an earlier litigation, survived, and now benefit from several favorable court rulings. The targeted industry includes the major cannabis industry leaders and supports a substantial damage model. The monetization project discussed below justifies the significant investment necessary for success.

Additional info from OTC:
Our patent portfolio held by Nascent Pharma Holdings, Inc. in its Nascent Pharma, LLC-Division includes three issued patents with claims to popular cannabis and hemp-based products and manufacturing methods that dominate the cannabis, hemp and CBD industry. The patents were tested in an earlier litigation, survived, and now benefit from several favorable court rulings. The targeted industry includes the major cannabis industry leaders and supports a substantial damage model. The monetization project discussed below justifies the significant investment necessary for success.

No news found.